BIIB110
Phase 2
BiogenBIIB110 is one of 26 therapeutic programs targeting Migraine. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
357 competitors in Migraine
#DrugCompanyPhaseTrials
1Aimovig
AmgenPreclinical
Emgality
Eli LillyPreclinical
Vyepti
LundbeckPreclinical
Savella
AbbViePreclinical
Bayer Aspirin
BayerPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Cervidil
PfizerPreclinical
Viagra
VViatris Specialty LLC
Preclinical
Pristiq
PPrism Pharmaceuticals
Preclinical
Bupivacaine Only
Pacira Pharmaceuticals, IncPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for BIIB110. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company